• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Glargine and liraglutide are effective glucose-lowering medications in type 2 diabetes

byDavid XiangandKiera Liblik
September 26, 2022
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to sitagliptin and glimepiride, glargine and liraglutide were more effective in achieving target glycated hemoglobin levels in patients with type 2 diabetes.

2. All four medications, when used adjunctive to metformin, significantly decreased glycated hemoglobin levels.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Type 2 diabetes affects more than 30 million adults in the United States and more than 500 million adults worldwide. Most recommendations for the management of glycemia in persons with type 2 diabetes include metformin as the first-line medication to be used, with a second medication added when needed to achieve the glycated hemoglobin level of less than 7%. However, there is a gap in knowledge as to the comparison between the various choices for adjunctive glucose-lowering medications. These include insulin, sulfonylureas, glucagon-like peptide-1 agonists, and dipeptidyl-peptidase 4 inhibitors. Overall, this study found that all four medications (glargine, glimepiride, liraglutide, and sitagliptin) improved glycated hemoglobin levels when added to metformin, though glargine and liraglutide were more effective in achieving and maintaining target glycated hemoglobin levels. This study was limited by factors such as the exclusion of thiazolidinediones and sodium-glucose cotransporter-2 inhibitors, the trial being unblinded, and medication adjustments being made faster than adjustments would typically be made in the clinical setting. Nevertheless, these study’s findings are significant, as they demonstrate that glargine, glimepiride, liraglutide, and sitagliptin all improve glycated hemoglobin levels when added to metformin, though glargine and liraglutide provide the most significant benefit.

Click to read the study in NEJM

Relevant Reading: Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes

RELATED REPORTS

2 Minute Medicine Rewind June 30, 2025

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

Food compounds associated with disease activity in inflammatory bowel disease 

In-Depth [randomized controlled trial]: This multicenter, parallel-group, comparative-effectiveness clinical trial was conducted across 36 clinical centers. Patients who had type 2 diabetes that had been diagnosed at or after the age of 30 years, and had known diabetes for less than 10 years were eligible for the study. Patients who had a glycated hemoglobin level of over 8.5% or under 6.8% were excluded from the study. The primary outcome measured was a glycated hemoglobin level, measured quarterly, of 7.0% or higher that was subsequently confirmed. The secondary metabolic outcome was a confirmed glycated hemoglobin level greater than 7.5%. Outcomes in the primary analysis were assessed via the intention-to-treat principle and Kaplan-Meier plots and Cox proportional-hazards models to assess differences among the treatment groups. Based on the primary analysis, the cumulative incidence of a glycated hemoglobin level of 7.0% or higher differed significantly among the four groups (p<0.001 among all four groups). The rates with glargine (26.5 per 100 participant-years) and liraglutide (26.1 per 100 participant-years) were similar and lower than those with glimepiride (30.4 per 100 participant-years) and sitagliptin (38.1 per 100 participant-years). Among participants with higher baseline glycated hemoglobin levels, there appeared to be an even greater benefit with glargine, liraglutide, and glimepiride than with sitagliptin. Overall, this study demonstrates that all four medications, when added to metformin, significantly decreased glycated hemoglobin levels. Though glargine and liraglutide were significantly more effective in achieving and maintaining target glycated hemoglobin levels.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologychronic diseasediabetesdiabetes mellitusendocrinologyglargineglimepirideglycemic controlglycemic indexliraglutidemetforminsitagliptintype 2 diabetes
Previous Post

Selpercatinib showed promising clinical activity in tumour-agnostic patients with RET­ fusion-positive cancers other than thyroid and lung cancer

Next Post

More permissive parameters for active surveillance eligibility is potentially possible in slow-growing thyroid cancers

RelatedReports

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Weekly Rewinds

2 Minute Medicine Rewind June 30, 2025

June 30, 2025
Chronic Disease

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

June 27, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Food compounds associated with disease activity in inflammatory bowel disease 

June 25, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
Next Post

More permissive parameters for active surveillance eligibility is potentially possible in slow-growing thyroid cancers

Unpaid caregivers of older adults experience emotional, physical, and financial difficulty

Increased pre-chemotherapy inflammatory biomarkers (IL-6 and CRP) correlated to increased risk of frailty post-chemotherapy in older breast cancer patients

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy
  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.